Abstract
No public abstract is available from the verified source records.
Cristina Marrocchio, Nicola Sverzellati
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Idiopathic pulmonary fibrosis: state of the art for 2023
10.1183/13993003.00957-2022 · 2023
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
10.1164/rccm.202202-0399st · 2022
Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality
10.1148/radiol.2463062200 · 2008
Towards the adoption of quantitative computed tomography in the management of interstitial lung disease
10.1183/16000617.0055-2023 · 2024
Machine learning in radiology: the new frontier in interstitial lung diseases
10.1016/s2589-7500(22)00230-8 · 2023
Quantification of interstitial lung diseases, from the AJR special series on quantitative imaging
10.2214/ajr.24.32053 · 2025
Meaningful thresholds for change in quantitative CT– derived fibrosis extent in idiopathic pulmonary fibrosis
10.1093/ajrccm/aamag245
Minimal clinically important difference: defining what really matters to patients
10.1001/jama.2014.13128 · 2014
Minimal clinically important difference in idiopathic pulmonary fibrosis
10.1183/20734735.0345-2020 · 2021
Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis
10.1183/13993003.01384-2018 · 2018
Minimum clinically important difference in quantitative lung fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab
10.1136/bmjopen-2024-094559 · 2025
Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on “feels, functions, survives.” Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency
10.1164/rccm.202312-2213so · 2024
Sources of variation in quantitative computed tomography of the lung
10.1097/rti.0b013e31829efbe9 · 2013
Quantitative CT analysis of diffuse lung disease
10.1148/rg.2020190099 · 2020
No additional external references are available.